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a b s t r a c t
The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore,
there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evi-
dent that deregulation of epigenetic mechanisms plays an important role in pancreatic carcinogenesis.
This review focuses on the exploitation of drugs that alter histone modiﬁcations, DNA methylation and
microRNA expression as options for the treatment of pancreatic cancer.
 2014 Elsevier Ltd. All rights reserved.
Introduction
Pancreatic cancer is one of the most aggressive of all human
malignancies. It is the fourth leading cause of cancer-related death
among men and women in the USA and Western Europe with a
5-year survival about 6% [1,2]. Early detection is difﬁcult because
of the absence of disease-speciﬁc symptoms and a reliable bio-
marker. Therefore, the majority of patients present with locally
advanced or metastatic disease [3]. For years, the standard
treatment for patients with advanced pancreatic cancer has been
the nucleoside analogue gemcitabine, which showed improved
alleviation of disease-related symptoms over 5-ﬂuorouracil (5FU)
treatment [4]. Subsequently, the epidermal growth factor receptor
(EGFR) inhibitor erlotinib was found to have a small, but signiﬁcant
survival beneﬁt in combination with gemcitabine over gemcitabine
alone, albeit with more serious adverse effects of treatment [5,6].
Furthermore, the FOLFIRINOX regimen (oxaliplatin, irinotecan, ﬂu-
orouracil, and leucovorin) also showed a signiﬁcant survival bene-
ﬁt over gemcitabine [7]. However, the gained survival advantage
remains limited, at the cost of more toxicity. Therefore, there is
an urgent need for new therapeutic options in pancreatic cancer.
This review will focus on the use of drugs that target epigenetic
regulation for the treatment of pancreatic cancer.
Epigenetics
In 2008, the core signaling pathways affected in pancreatic can-
cer were revealed [8]. The best characterized genes in pancreatic
cancer are the oncogene KRAS, and the tumor-suppressor genes
TP53, SMAD4 and CDKN2A [8,9]. The identiﬁcation of these path-
ways and genetic alterations provides potential molecular targets
for drug development. But despite of encouraging results in pre-
clinical studies, many drugs did not show a survival beneﬁt over
gemcitabine [10–12]. Recently, other molecular events, such as
epigenetic alterations, are identiﬁed to contribute to the develop-
ment of pancreatic cancer. Epigenetics is deﬁned as the study of
heritable changes in gene expression caused by mechanisms other
than changes in the underlying DNA sequence. The best known
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epigenetic mechanisms are histone modiﬁcations, DNA methyla-
tion and microRNAs (miRNAs) (Fig. 1). These epigenetic mecha-
nisms might serve as suitable targets for therapeutic
interventions as they play a pivotal role in the regulation of cellular
processes.
Histone modiﬁcations
The DNA of eukaryotic cells is packaged into the nucleus in the
form of chromatin, which is made up of nucleosomes. A nucleo-
some consists of an octameric histone core with DNA tightly
wrapped around it. In general, this core consists of dimers of his-
tone proteins H2A, H2B, H3, and H4. These histones all have a ﬂex-
ible N-terminus protruding from the core, called histone tail, which
can be post-translationally modiﬁed, leading to changes in chro-
matin compaction [13]. Two major histone modiﬁcations are acet-
ylation and methylation.
Acetylation is mediated by histone acetyltransferases (HATs)
and can occur on lysine residues in histone tails (Fig. 1). Lysine
acetylation promotes transcriptional activation; it neutralizes the
positive charge of lysine, thereby loosening the interaction with
negatively charged DNA and enabling transcription. Furthermore,
it recruits ATP-dependent chromatin remodeling complexes such
as the SWI/SNF complex, which facilitate the binding of transcrip-
tional proteins by decondensing the DNA [13]. Acetylation of his-
tone tails is a reversible process. Histone deacetylases (HDACs)
remove acetyl groups from the histone tails. This restores the posi-
tive charge on the lysine residue and reestablishes the electrostatic
interaction with DNA, thereby repressing transcription [14].
Histone methylation is mediated by histone methyltransferases
(HMTs) and can occur on lysine and arginine residues (Fig. 1).
Methylation of lysine (K) 9 and 27 in the histone tail of H3 induces
the formation of heterochromatin [13,15,16]. This H3K9 methyla-
tion recruits heterochromatin protein 1 (HP1), which can then oli-
gomerize with other HP1 proteins to form heterochromatin.
Furthermore, HP1 can recruit DNA methyltransferases (DNMTs)
and HMTs to propagate the repressive mark along the DNA [15].
Transcriptional silencing induced by H3K27 methylation is
mediated by polycomb repressor complexes PRC1 and PRC2.
PRC2 functions as a HMT that adds methyl groups to H3K27.
H3K27 methylation by PRC2 forms a binding site for PRC1, which
condenses the DNA into heterochromatin [16]. Furthermore,
polycomb complexes can associate with DNMTs [17].
DNA methylation
DNAmethylation is the covalent addition of a methyl group to a
cytosine in mainly CpG dinucleotides and is mediated by DNMTs
(Fig. 1). It is a key element in the formation and maintenance of
condensed chromatin. DNA methylation induces transcriptional
silencing by interfering with the binding of transcriptional proteins
and it can recruit methyl-CpG binding proteins (MBPs), which in
turn recruit HDACs leading to transcriptional repression [15,18].
MicroRNAs
Although miRNAs are under epigenetic control themselves, they
too are heritable regulators of gene expression without changing
the underlying DNA sequence [19]. Unlike histone modiﬁcations
and DNA methylation, miRNAs are post-transcriptional regulators
of gene expression. They are small non-coding RNAs that can
base-pair with complementary protein coding mRNAs, thereby
inhibiting translation or inducing degradation of these mRNAs
(Fig. 1) [20]. There are more than 1800 human miRNAs that can
have multiple targets [21]. They are predicted to regulate approx-
imately 30% of the protein coding genome, including important
cellular processes such as cell growth, differentiation and apopto-
sis [20,22].
Therapeutic options of epigenetic targeting in pancreatic cancer
Several studies have investigated the role of epigenetic mecha-
nisms in pancreatic cancer and the results reﬂect their importance
in pancreatic cancer development and progression.
HDACs have been shown to regulate important cellular pro-
cesses such as proliferation, apoptosis, differentiation, migration
and angiogenesis in cancer [23]. In pancreatic cancer, several
HDACs are overexpressed and our understanding of the down-
stream effects is increasing [24]. Low expression of tumor-suppres-
sor gene TGFBR2 is observed in 50% of pancreatic cancers, but
genetic alterations of TGFBR2 are rare [25–27]. It has been shown
that HDAC1 and HDAC2/SIN3a are recruited to the TGFBR2 pro-
moter, leading to its repression [28–30]. Also, Von Burstin et al. ob-
served recruitment of SNAIL together with HDAC1 and HDAC2 to
the promoter of CDH1 in a highly metastatic pancreatic cancer cell
line [31]. CDH1 encodes for the epithelial marker E-cadherin. Loss
of E-cadherin is a key element in epithelial-mesenchymal
Fig. 1. Schematic overview of epigenetic mechanisms. When nucleosomes (blue cylinders) are densely compacted (left), the chromatin is in a repressed state. This repressive
signal is induced and maintained by several proteins like HDACs. Activation is mediated by HATs and chromatin remodelling complexes, which decondense chromatin (right).
DNA methylation is regulated by DNMTs. In addition, miRNAs can silence gene expression by associating with mRNA of transcribed genes. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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transition (EMT), leading to cancer invasion and metastasis [32].
Overexpression of HDAC2 leads to apoptotic resistance of cancer
cells via silencing of the death-inducing NOXA gene and attenuates
TRAIL-induced apoptosis of pancreatic cancer cells [33,34]. In addi-
tion, HDAC3 has been shown to activate SKP2 which recognizes
phosphorylated p27Kip1, targeting the cell cycle regulator for ubiq-
uitination and subsequent degradation by the proteasome [24].
HMTs are also involved in pancreatic cancer. EZH2 is a HMT of
the PRC2 complex [16]. Nuclear accumulation of EZH2 is a hall-
mark of poorly differentiated pancreatic cancer. Genetic depletion
of EZH2 results in re-expression of cell cycle regulator p27Kip1 and
decreased pancreatic cancer cell proliferation. In addition, it sensi-
tized pancreatic cancer cells to doxorubicin and gemcitabine [35].
Another HMT implicated in pancreatic cancer is SUV39H1. Baum-
gart et al. have shown that SUV39H1 is recruited by NFAT to the
p15INK4b promoter in pancreatic cancer leading to H3K9 trimethy-
lation and subsequent binding by HP1 resulting in a repressed
chromatin state and gene silencing [36].
Many promoters of tumor-suppressor genes are hypermethy-
lated in pancreatic cancer [37,38]. One typical example is the clas-
sic tumor-suppressor gene CDKN2A, which encodes for cell cycle
regulator p16 and undergoes methylation-induced silencing in al-
most all those pancreatic cancers (around 15–20% of cases) that do
not have bi-allelic genetic inactivation of CDKN2A [39].
An increasing amount of miRNAs has also been associated with
pancreatic cancer [40]. For example, miR-21 is upregulated in pan-
creatic cancer [41,42]. Overexpression of miR-21 precursor in pan-
creatic cancer cells resulted in increased proliferation, invasion and
chemoresistance compared with control cells [41]. MiR-21 targets
many apoptosis related genes such as PTEN and PDCD4, leading to
inhibition of apoptosis and consequently increased tumorigenicity
[43]. Furthermore, miR-21 positively correlated with the mRNA
expression of invasion-related genes, matrix metalloproteinase-2
and 9, and vascular endothelial growth factor [41].
These observations emphasize the importance of epigenetics in
pancreatic carcinogenesis. Moreover, they led to the investigation
of histone deacetylase inhibitors (HDACIs), histone methyltransfer-
ase inhibitors (HMTIs), DNA demethylating strategies and miRNA
expression modulators as therapeutic options in pancreatic cancer
(Table 1). Although other epigenetic proteins, such as HATs, are
also implicated in cancer, there are currently no studies investigat-
ing drugs targeting these proteins in the context of pancreatic
cancer.
Histone deacetylase inhibitors
HDACs can be divided into four classes. The class I, II and IV
HDACs rely on zinc-dependent catalysis for their activity. Class III
HDACs are called SIRT 1 to 7 and use NAD+ as a co-factor for
deacetylation activity [24,44,45]. Class I HDACs 1, 2, 3 and class
II HDAC 7 have been reported to be overexpressed in pancreatic
cancer [24,46–50]. Four different types of HDACIs are used in pan-
creatic cancer studies: hydroxamic acids, short-chain fatty acids,
cyclic peptides and benzamides (Table 1) [45].
Hydroxamic acids
Hydroxamic acids are metal chelators, which can scavenge the
zinc ions necessary for HDAC activity. Furthermore, they can bind
to the active site of HDACs [51]. The hydroxamic acid HDACIs most
studied in pancreatic cancer are trichostatin A, vorinostat, panobi-
nostat and belinostat (Table 1) [52].
Trichostatin A (TSA) is a natural HDACI that inhibits class I and
class II HDACs [53]. Its effect has been studied in vitro in many pan-
creatic cancer cell lines and also in vivo using xenografts in nude
mice [54–57]. Although the results of these studies indicate that
TSA is a very potent anti-tumor agent, it has not been tested in
clinical trials [58].
Vorinostat is a synthetic compound, which like TSA, is a class I/II
HDACI [59]. Vorinostat is approved by the U.S. Food and Drug
Administration for treatment of relapsed or refractory cutaneous
T cell lymphoma (CTCL) [60]. In 2007, Arnold et al. were the ﬁrst
to describe the effect of vorinostat in pancreatic cancer cell lines.
They showed that vorinostat induced G1 cell cycle arrest via upreg-
ulation of p21 in BxPC-3 cells and COLO-357 cells, but not in gem-
citabine resistant PANC-1 cells. Furthermore, vorinostat had an
additive effect on growth inhibition with gemcitabine in BxPC-3
and COLO-357 cells, and sensitized PANC-1 cells to gemcitabine
[61]. In contrast, Kumagai et al. (2007) showed that vorinostat
treatment did result in growth inhibition of PANC-1 cells and in-
duced upregulation of p21 in these cells and that vorinostat in-
duced G2/M instead of G1 cell cycle arrest [62]. More recent
studies investigated the effect of vorinostat in combination therapy.
In vitro it is found that the combination of gemcitabine, the protea-
some inhibitor bortezomib and vorinostat resulted in the greatest
inhibitory effect on cell growth. Experiments in vivo in nude mice,
however, showed no signiﬁcant beneﬁt of the triple-combination
over gemcitabine with bortezomib [63]. Another study byMillward
et al. (2012), currently in a phase I clinical trial, reported marked
synergy of the proteasome inhibitor marizomib and vorinostat
in vitro in tumor cell lines derived from patients with non-small cell
lung cancer, melanoma and pancreatic carcinoma. However, in the
clinical trial so far, they detected no tumor response [64]. Although
little encouraging results were found in pre-clinical and clinical tri-
als, the anti-cancer effect of vorinostat observed in vitro and in other
cancers triggers researchers to set up new clinical trials with vori-
nostat in pancreatic cancer. In an ongoing phase I/II clinical trial,
the combination of vorinostat with radiation therapy and 5FU is
tested in patients with locally advanced pancreatic cancer [65]. Fur-
thermore, a phase I trial is recruiting participants to evaluate the
combination of vorinostat, capecitabine, a prodrug of 5FU, and radi-
ation therapy in patients with non-metastatic pancreatic cancer
[66].
Panobinostat inhibits all zinc dependent HDAC classes and is
therefore called a pan-HDAC inhibitor [67]. It was tested in the
context of pancreatic cancer for the ﬁrst time in 2008 by Haefner
et al. They showed that panobinostat induced G2/M cell cycle ar-
rest, upregulation of p21 and apoptosis in vitro. In vivo, it signiﬁ-
cantly reduced tumor mass in nude mice and potentiated the
efﬁcacy of gemcitabine, but apoptosis was only slightly increased
and there was no signiﬁcant reduction of cell proliferation [68].
Panobinostat was recently tested in a phase II clinical trial in com-
bination with bortezomib in patients with pancreatic cancer pro-
gressing on gemcitabine therapy. Unfortunately, the study was
terminated after inclusion of seven patients due to a complete lack
of treatment responses and early grade 4 thrombocytopenia and
diarrhea [69]. However, a recent study with panobinostat in com-
bination with PI3K and mTOR inhibitor BEZ235 showed growth
inhibition both in vitro and in vivo using xenografts in nude mice
[70].
Belinostat is a relatively new pan-HDAC inhibitor [67]. In
2010, it was tested in a phase I clinical trial in combination with
carboplatin, and/or paclitaxel in patients with solid tumors,
including three cases of pancreatic cancer. Interestingly, one of
the pancreatic cancer patients had a partial response to belino-
stat with carboplatin [71]. Like panobinostat, belinostat has also
been tested in a pre-clinical study in combination with bortezo-
mib. The results showed synergistic antiproliferative and pro-
apoptotic effects of the two drugs in pancreatic cancer cell lines
[72]. More recently, two studies showed that belinostat induces
growth inhibition, in vitro and in vivo in immunodeﬁcient mice,
alone or synergistically with gemcitabine [73,74].
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Short-chain fatty acids
Short-chain fatty acids (SCFAs) are less potent HDACIs than
hydroxamic acids, presumably because they are not able to access
the zinc ion in the HDAC active-site pocket [75]. In pancreatic can-
cer, the best studied and most promising SCFAs are valproic acid
and butyrate.
Valproic acid (VPA) is a class I/IIa HDACI, which was ﬁrst dis-
covered as an antiepileptic drug. Later, the HDAC inhibitory
effects of VPA became apparent [76]. In a phase I clinical trial
of VPA and the anthracycline drug epirubicin in solid tumors,
one pancreatic cancer patient showed partial response to this
drug combination [77]. In vitro, VPA has shown to potently
down-regulate the proliferation and adhesion capacity of pancre-
atic cancer cells [78]. In 2011, two separate studies by Iwahashi
et al. in pancreatic cancer cell lines showed that VPA alone did
not induce signiﬁcant growth inhibition, but potentiated growth
inhibition by 5FU and the combination of gemcitabine and
Table 1
Epigenetic targeting strategies in pancreatic cancer.
Group Drug Important targets Clinical trial Results Ref.
HDAC inhibitors
Hydroxamic acids Trichostatin A HDAC class I and II
Vorinostat HDAC class I and II NCT00948688 In combination with marizomib; no tumour response
detected.
[64]
NCT00948688 Ongoing: in combination with 5-FU and radiation therapy. [65]
NCT00983268 Ongoing: in combination with capecitabine and radiation
therapy.
[66]
Panobinostat HDAC pan-inhibitor In combination with bortezomib. Terminated because of lack
of response and early toxicity.
[69]
Belinostat HDAC pan-inhibitor
Short-chain fatty acids Valproic acid HDAC class I and II In combination with epirubicin. Partial response of one
pancreatic cancer patient.
[77]
NCT01333631 Ongoing: in combination with gemcitabine and radiation
therapy.
[81]
Butyrate HDAC class I and II
Cyclic peptides Romidepsin HDAC class I and II, G9a
and SUV39H1
NCT00379639 In combination with gemcitabine. Adverse events but also
partial response and stable disease in patients with solid
tumour including pancreatic cancer.
[90,91]
Benzamides Entinostat HDAC class I The only patient with pancreatic cancer was removed due to
disease progression.
[93]
In combination with 13-cis retinoic acid. No tumour response,
the only patient with pancreatic cancer showed stable disease.
[94]
HMT inhibitors BRD4770 G9a
Romidepsin HDAC class I and II, G9a
and SUV39H1
See romidepsin cyclic peptides.
Curcumin/CDF EZH2/miR-101, miR-200,
miR-21, miR-22 and miR-
199a⁄
Alone and in combination with gemcitabine. Some tumour
responses to curcumin.
[99–
101]
NCT00094445 Ongoing: single agent study. [102]
DNA methylation 5-aza-20-
deoxycytidine/
5-azacytidine
Methylated CpG islands NCT01167816 Ongoing: in combination with gemcitabine. [108]
NCT01845805 Ongoing: single agent study. [109]
Curcumin/EF31/
UBS109
DNMT1 See curcumin/CDF HMT inhibitors.
Modulators of miRNA
expression
Retinoic acid
receptor
antagonists
miR-10a
Indole-3-carbinol miR-21
Lentiviral vector miR-21
Curcumin/CDF EZH2/miR-101, miR-200,
miR-21, miR-22 and miR-
199a⁄
See curcumin/CDF HMT inhibitors.
Garcinol miR-21
3,30-
diindolylmethane
(DIM) and
isoﬂavone
miR-200, miR-146a and
let-7
5-aza-20-
deoxycytidine/
Vorinostat
miR-34a See vorinostat hydrozamic acids and 5-aza-20-deoxycytidine /
5-azacytidine DNA methylation.
Trichostatin A miR-200c and miR-21
Metformin miR-101, miR-200, let-7
and miR-26a
NCT01210911 Ongoing: in combination with erlotinib and gemcitabine. [129]
NCT01167738 Ongoing: in combination with capecitabine, cisplatin,
epirubicin and gemcitabine.
[130]
NCT01666730 Ongoing: in combination with oxaliplatin, leucovorin calcium,
ﬂuorouracil.
[131]
NCT01488552 Ongoing: in combination with gemcitabine, nab-paclitaxel,
FOLFORINOX.
[132]
Glargine miR-95
Nanovectors miR-34a, miR143/145
and let-7
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pegylated interferon-a2b [79,80]. Recently, a phase II study has
been set up to evaluate the toxicity and efﬁcacy of VPA in com-
bination with gemcitabine and radiotherapy [81].
Butyrate is a class I/II HDACI [82]. It has been shown to induce
apoptosis and inhibits invasion in pancreatic cancer cell lines and
is suggested to potentiate chemotherapy [83,84]. However, it is
also reported to have poor pharmacological properties such as a
short half-life and ﬁrst-pass hepatic clearance [85]. Prodrugs of
butyrate with better pharmacological properties could provide an
alternative therapeutic option as is demonstrated by the growth
inhibition of pancreatic cancer cells by the butyrate prodrug tribu-
tyrin [86]. (Pre-)clinical trials are needed to assess the therapeutic
value of butyrate derivatives.
Cyclic peptides
Romidepsin is a pentapeptide that can interact with the zinc ion
in the active site of the HDACs and it is classiﬁed as a class I/II
HDACI. In 2009, romidepsin was approved by the U.S. FDA for
treatment of patients with CTCL [87]. Romidepsin induces G1 or
G2/M cell cycle arrest and subsequent apoptosis in refractory hu-
man pancreatic cancer cells [88]. Furthermore, romidepsin also in-
duces growth inhibition in vivo in a human pancreatic cancer
xenograft [89]. Recently, a phase I study by Jones et al. (2012)
tested romidepsin in combination with gemcitabine in solid tu-
mors, including pancreatic cancer. Although additive hematologi-
cal toxicity of the combination was observed, the disease
stabilization in 14 patients and partial response in two patients
warrant further research [90,91].
Benzamides
Entinostat is a synthetic benzamide derivative that inhibits
class I HDACs [67]. Its anti-tumor activities were ﬁrst studied in
1999 by Saito et al. They reported strong anti-tumor efﬁcacy
against human cancers in nude mice [92]. In 2008, a phase I study
of entinostat included one metastatic pancreatic cancer patient,
who had disease progression [93]. A recent phase I study of entino-
stat in combination with 13-cis retinoic acid in solid tumors, again
included one pancreatic cancer patient who reached prolonged sta-
ble disease [94].
Inhibiting histone methyltransferases
The use of HMTIs in pancreatic cancer is rare. Recently, Yuan
et al. (2012) described the discovery of a novel HMTI called
BRD4770. This HMTI inhibits HMT G9a, which mediates H3K9
methylation. They showed that BRD4770 induced cellular senes-
cence in PANC-1 cells [95]. Furthermore, they found that gossypol,
a natural product from cottonseeds and a putative BH3 mimetic,
acts in a synergistic manner with BRD770, inducing autophagy-re-
lated cell death in PANC-1 cells [96]. The therapeutic value of these
new drugs in vivo is unknown.
With hindsight, HMT inhibition was observed for agents target-
ing other cellular processes. For example, Wu et al. (2008) have
shown that the HDACI romidepsin suppresses expression of HMTs
G9a and SUV39H1 [97]. Bao et al. (2012) found that diﬂuorinated-
curcumin (CDF), an analogue of curcumin, increases expression of a
panel of tumor-suppressor miRNAs, including miR-101, in vitro.
Re-expression of miR-101 mediated by CDF reduced HMT EZH2
levels and inhibited cell growth. Furthermore, reduced EZH2 levels
and tumor growth inhibition was also observed in vivo in an ortho-
topic xenograft model of human pancreatic cancer [98]. As curcu-
min as well as CDF inhibit NF-jB, a transcription factor that is often
constitutively active in pancreatic cancer, it should be taken into
account that the anti-tumor effects observed of curcumin or CDF
might not be through EZH2 suppression. Phase II trials of curcumin
alone and in combination with gemcitabine showed that curcumin
was well tolerated and might have some biological activity in
patients with pancreatic cancer [99–101]. Furthermore, there is
another ongoing phase II clinical trial of curcumin in patients with
advanced pancreatic adenocarcinoma [102].
DNA demethylation
As mentioned before, it has been well established that many
genes are hypermethylated in pancreatic cancer [37,38]. DNA
demethylating agents such as the cytidine analog 5-azacytidine
and other DNMT1 inhibitors have been used to reduce methylation
in pancreatic cancer.
Intracellularly, 5-azacytidine is converted to the activated
5-aza-deoxycytidine-triphosphate, and subsequently incorporated
into DNA. This results in an irreversible covalent complex with
DNMT1, triggers proteasome-mediated DNMT1 degradation, and
leads to reduced DNA methylation levels [103]. In 2005, Missiaglia
et al. have shown that 5-aza-deoxycytidine (5-aza-dC) treatment
results in global DNA demethylation, growth inhibition and apop-
tosis of pancreatic cancer cell lines. Furthermore, they showed that
pretreatment with 5-aza-dC increased the sensitivity of pancreatic
cancer cells to other chemotherapy agents, including gemcitabine
[104]. However, in 2003, Sato et al. showed that 5-aza-dC treat-
ment induced aberrant expression of matrix metalloproteinases
(MMPs) in pancreatic cancer cell lines, promoting tumor invasion
and metastasis [105]. In 2009, Kumari et al. showed that treatment
of pancreatic cancer cell lines with 5-azacytidine resulted in the
reduction of telomerase activity. Telomerase activity, exerted by
TERT, is a key component of cellular immortality and in this way
may play a role in tumorigenesis. The mechanism behind the
5-azacytidine induced loss of telomerase activity is far from clear.
Although, counterintuitive it may be that demethylation of the CpG
island at the TERT promoter directly leads to reduced expression
[106].
Recently, Shakya et al. (2013) tested 5-aza-dC in an aggressive
stroma-rich mouse model of pancreatic carcinoma. They showed
that 5-aza-dC was able to slow disease progression and even tran-
sient tumor growth inhibition [107]. Currently, a phase I trial is
recruiting patients to determine the maximum tolerated dose of
5-azacytidine and gemcitabine in subjects with previously un-
treated and unresectable pancreatic cancer [108]. Furthermore, a
phase II trial is set up to assess the effect of 5-azacytidine on pro-
gression free survival in patients with resected pancreatic cancer
[109].
Another recent study by Nagaraju et al. (2013) investigated the
effect of curcumin and two curcumin analogues EF31 and UBS109
on DNMT1 expression in pancreatic cancer. Treatment of pancre-
atic cancer cell lines with curcumin, EF31 and UBS109 resulted in
growth inhibition, downregulation of DNMT1, decreased DNA
methylation and re-expression of silenced genes such as CDKN2A.
Furthermore, they show that EF31 and UBS109 reduce DNMT1
expression and DNA methylation, and re-express p16. In addition,
these agents increased the sensitivity of pancreatic cancer cells to
the combination of 5FU and oxaliplatin. In all these experiments,
UBS109 proved to be the most potent drug [110].
MicroRNA expression modulators
In pancreatic cancer, both overexpression and downregulation
of miRNAs have been associated with poor overall survival and
prognosis [111]. Many studies have evaluated the effect of inhibit-
ing overexpressed miRNAs and re-expressing silenced miRNAs [40]
and have thereby attempted to identify new therapeutic applica-
tions. The miRNAs involved in pancreatic cancer have been
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summarized extensively by others [111–114]. Here, we focus on
modulators of miRNA expression tested in the context of pancre-
atic cancer.
In 2009, Weiss et al. showed that miR-10a is overexpressed in
metastatic pancreatic cancer. Furthermore, they show that miR-
10a is a retinoid acid target and that retinoic acid receptor antag-
onists effectively repress miR-10a expression and completely block
metastasis in zebraﬁsh xenotransplants [115]. Currently, no clini-
cal trials are investigating these agents in pancreatic cancer [58].
Also miR-21 is upregulated in pancreatic cancer. It is associated
with apoptosis inhibition resulting in chemoresistance [40]. In vitro
studies have shown that miR-21 inhibition sensitizes cells to gem-
citabine and 5FU. Recently, Paik et al. (2013) have shown that in-
dole-3-carbinol (I3C) suppressed miR-21 expression and
sensitized PANC-1 cells to gemcitabine [116]. Furthermore, Sicard
et al. (2013) reported miR-21 downregulation using lentiviral vec-
tors in vitro and in vivo. They show that targeting miR-21 strongly
inhibits pancreatic cancer tumor growth [117].
In 2008 already, Sun et al. demonstrated that curcumin upreg-
ulated miR-22 and downregulated miR-199a⁄ in pancreatic cancer
cell lines. Furthermore, upregulation of miR-22 suppressed the
ESR1 and SP1 protein expression, suggesting a new mechanism
by which curcumin mediates its effects on cell growth and apopto-
sis [118]. As mentioned before, curcumin analogue CDF is able to
re-express miR-101 leading to tumor growth inhibition in vivo in
immunodeﬁcient mice via EZH2 downregulation [98]. Further-
more, CDF has been shown to induce re-expression of miR-200,
which is also downregulated in pancreatic cancer [40]. Re-expres-
sion of miR-200 has been shown to result in upregulation of apop-
tosis regulator PTEN, and downregulation of matrix
metalloproteinase-1, which is often activated and expressed in tu-
mor cells with signiﬁcant invasive properties, and is associated
with poor prognosis of patients [119]. In addition, CDF was found
to downregulate miR-21 expression and sensitize cells to gemcita-
bine [120,121].
Garcinol, a natural agent associated with anti-cancer activity,
has been shown to alter the expression of several miRNAs, includ-
ing downregulation of miR-21. It can synergize with gemcitabine
to inhibit cell proliferation and induce apoptosis in pancreatic can-
cer cells [122]. Furthermore, garcinol has been shown to synergize
with curcumin to inhibit growth and induce apoptosis in pancre-
atic cancer cells [123]. Other natural agents like 3,30-diindolylme-
thane (DIM) and isoﬂavone have been shown to upregulate the
expression of miR-200 and let-7 in gemcitabine resistant cells,
thereby reducing the EMT characteristics of these cells [124]. Fur-
thermore, pancreatic cancer cells treated with DIM or isoﬂavone
showed increased miR-146a expression and caused a downregula-
tion of epidermal growth factor receptor, metastasis-associated
protein 2, interleukin-1 receptor associated kinase 1, and NF-jB
with subsequent inhibition of pancreatic cancer cell invasion [125].
In 2011, Nalls et al. demonstrated that treatment of pancreatic
cancer stem cells with 5-Aza-dC or HDACI vorinostat inhibits cell
proliferation, induces apoptosis, and reduces invasive potential.
They demonstrate that this is due to restored expression of
miR-34a, which targets among others the Notch signaling compo-
nent RBPJ and EMT inducer ZEB1 [126]. Furthermore, HDACI TSA
inhibits cell proliferation in pancreatic cancer cells through upreg-
ulation of miR-200c and downregulation of miR-21, which results
in cell cycle arrest and increased apoptosis [127]. Recently, Bao
et al. (2012) showed that metformin, a diabetes mellitus drug asso-
ciated with a reduced risk of pancreatic cancer, caused re-expres-
sion of miR-101, miR-200, let-7 and miR-26a. Treatment of
pancreatic cancer cell lines with metformin signiﬁcantly decreased
cell survival, clonogenicity, sphere-forming capacity, and increased
disintegration of spheres in both gemcitabine-sensitive and gem-
citabine-resistant pancreatic cancer. Furthermore, it has been
shown to inhibit tumor growth in PANC-1 xenografts [128]. Cur-
rently, four phase II clinical trials are recruiting patients to investi-
gate the effect of metformin in combination with other drugs such
as gemcitabine and capecitabine [129–132]. At the same time, Li
et al. (2012) demonstrated that high doses of glargine, an insulin
analog used in diabetes mellitus, altered miRNA expression. Most
obvious was the raise of miR-95, which can cause increased pan-
creatic cancer cell proliferation, invasion and migration and inhib-
its apoptosis [133].
Upcoming strategies to directly modify miRNA levels are
replacement and inhibition therapies. Inhibition of overexpressed
miRNAs can be done with antisense oligonucleotides, as studied
by Park et al. (2009). They showed that antisense inhibition of
miR-21 and miR-221 resulted in cell cycle arrest and/or induc-
tion of apoptosis in vitro, and sensitizes pancreatic cancer cells
to the effects of gemcitabine [134]. Lentiviral vectors and
non-viral lipid based nanoparticles can be used for restitution
of miRNAs. Pramanik et al. (2011) demonstrated that systemic
intravenous delivery with miR-34a or miR-143/145 nanovectors
inhibited growth of subcutaneous MiaPaCa-2 xenografts [135].
Restoring let-7 levels in pancreatic cancer cells through plas-
mid-based synthetic miRNAs or lentiviral induction inhibited cell
proliferation, KRAS expression, and mitogen-activated protein ki-
nase activation. Unfortunately, inhibition of tumor growth after
intratumoral gene transfer failed [136].
Conclusion
This review shows that a rapidly increasing number of studies is
focused at drugs that target epigenetic mechanisms. Although
promising results have been obtained in many in vitro and in vivo
studies, clinical trials with pancreatic cancer patients predomi-
nantly show disappointing outcomes [63,64,69,93,94]. This might
be attributed to the lack of speciﬁcity of epigenetic drugs.
The targets and effects of epigenetic drugs are not fully eluci-
dated yet. These drugs might have numerous unknown adverse ef-
fects. Although epigenetic drugs are regarded as targeted therapies,
they often affect many different pathways and tissues by exerting
their effect throughout the whole genome in both tumor and nor-
mal cells. In addition, it is complicated to determine whether re-
ported responses to epigenetic drugs are strictly mediated via
epigenetic mechanisms [137]. For example, HDACIs are not only
involved in deacetylation of histone tails. A large number of other
non-histone proteins is also acetylated and can thus be affected by
HDACIs [23]. 5-aza-dC exerts its demethylating activity throughout
the whole genome. Thus, this drug leads to global hypomethyla-
tion, re-expression of hypermethylated tumor-suppressor genes,
but possibly also activation of oncogenes [105]. Furthermore,
new miRNAs and new targets of known miRNAs are continuously
discovered. Moreover, miRNA targeting not only affects pathways
involved in carcinogenesis but also normal pathways leading to
unwanted side effects.
The currently unknown effects of drugs targeting epigenetics
might play a role in the adverse effects and poor performance in
clinical trials. Careful review of research in other solid tumors
and, further research is needed to establish all targets and down-
stream effects of epigenetic targeting. This will provide a basis
for understanding the cause of adverse effects, tumor speciﬁcity
and drug resistance, and can ultimately lead to optimal drug regi-
mens in pancreatic cancer, patient selection and safety.
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